FOLFIRI plus BEvacizumab or aFLIbercept after FOLFOX-bevacizumab failure for COlorectal cancer (BEFLICO): An AGEO multicenter study.
Antineoplastic Combined Chemotherapy Protocols
/ adverse effects
Bevacizumab
/ adverse effects
Camptothecin
/ adverse effects
Colorectal Neoplasms
/ drug therapy
Female
Fluorouracil
/ adverse effects
Humans
Leucovorin
/ adverse effects
Male
Middle Aged
Proto-Oncogene Proteins B-raf
Receptors, Vascular Endothelial Growth Factor
Recombinant Fusion Proteins
aflibercept
bevacizumab
chemotherapy
metastatic colorectal cancer
Journal
International journal of cancer
ISSN: 1097-0215
Titre abrégé: Int J Cancer
Pays: United States
ID NLM: 0042124
Informations de publication
Date de publication:
01 Dec 2022
01 Dec 2022
Historique:
revised:
20
04
2022
received:
06
12
2021
accepted:
26
04
2022
pubmed:
15
7
2022
medline:
18
10
2022
entrez:
14
7
2022
Statut:
ppublish
Résumé
After failure of first line FOLFOX-bevacizumab for metastatic colorectal cancer (mCRC), adding either bevacizumab or aflibercept to second-line FOLFIRI increases survival compared to FOLFIRI alone. In this French retrospective multicentre cohort, we included patients with a mCRC treated with either FOLFIRI-aflibercept or FOLFIRI-bevacizumab. The primary endpoint was overall survival (OS), and secondary endpoints were progression-free survival (PFS), disease control rate (DCR: CR + PR + SD) and safety. We included 681 patients from 36 centers, 326 and 355 in the aflibercept and bevacizumab groups, respectively. Median age was 64.2 years and 45.2% of patients were men. Most patients had RAS-mutated tumors (80.8%) and synchronous metastases (85.7%). After a median follow up of 31.2 months, median OS was 13.0 months (95% CI: 11.3-14.7) and 10.4 months (95% CI: 8.8-11.4) in the bevacizumab and aflibercept groups, respectively (P < .0001). Median PFS was 6.0 months (95% CI: 5.4-6.5) and 5.1 months (95% CI: 4.3-5.6) (P < .0001). After adjustment on age, PS, PFS of first line, primary tumor resection, metastasis location and RAS/BRAF status, bevacizumab was still associated with better OS (HR: 0.71, 95% CI: 0.59-0.86, P = .0003). FOLFIRI-bevacizumab combination was associated with longer OS and PFS, and a better tolerability, as compared to FOLFIRI-aflibercept after progression on FOLFOX-bevacizumab.
Substances chimiques
Recombinant Fusion Proteins
0
aflibercept
15C2VL427D
Bevacizumab
2S9ZZM9Q9V
Receptors, Vascular Endothelial Growth Factor
EC 2.7.10.1
Proto-Oncogene Proteins B-raf
EC 2.7.11.1
Leucovorin
Q573I9DVLP
Fluorouracil
U3P01618RT
Camptothecin
XT3Z54Z28A
Types de publication
Journal Article
Multicenter Study
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
1978-1988Informations de copyright
© 2022 UICC.
Références
Brenner H, Kloor M, Pox C. Colorectal cancer. Lancet. 2014;383(9927):1490-1502.
Bergers G, Benjamin LE. Tumorigenesis and the angiogenic switch. Nat Rev Cancer. 2003;3(6):401-410.
Folkman J. Tumor angiogenesis: therapeutic implications. N Engl J Med. 1971;285(21):1182-1186.
Van Cutsem E, Cervantes A, Nordlinger B, Arnold D. Metastatic colorectal cancer: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2014;25(Suppl 3):iii1-iii9.
Hurwitz H, Fehrenbacher L, Novotny W, et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med. 2004;350(23):2335-2342.
Bennouna J, Sastre J, Arnold D, et al. Continuation of bevacizumab after first progression in metastatic colorectal cancer (ML18147): a randomised phase 3 trial. Lancet Oncol. 2013;14(1):29-37.
Giantonio BJ, Catalano PJ, Meropol NJ, et al. Bevacizumab in combination with oxaliplatin, fluorouracil, and leucovorin (FOLFOX4) for previously treated metastatic colorectal cancer: results from the Eastern Cooperative Oncology Group Study E3200. J Clin Oncol. 2007;25(12):1539-1544.
Saltz LB, Clarke S, Díaz-Rubio E, et al. Bevacizumab in combination with oxaliplatin-based chemotherapy as first-line therapy in metastatic colorectal cancer: a randomized phase III study. J Clin Oncol. 2008;26(12):2013-2019.
Baraniskin A, Buchberger B, Pox C, et al. Efficacy of bevacizumab in first-line treatment of metastatic colorectal cancer: a systematic review and meta-analysis. Eur J Cancer. 2019;106:37-44.
Van Cutsem E, Tabernero J, Lakomy R, et al. Addition of aflibercept to fluorouracil, leucovorin, and irinotecan improves survival in a phase III randomized trial in patients with metastatic colorectal cancer previously treated with an oxaliplatin-based regimen. J Clin Oncol. 2012;30(28):3499-3506.
Benson AB, Venook AP, Al-Hawary MM, et al. Colon cancer, version 2.2021, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw. 2021;19(3):329-359.
Tabernero J, Yoshino T, Cohn AL, et al. Ramucirumab versus placebo in combination with second-line FOLFIRI in patients with metastatic colorectal carcinoma that progressed during or after first-line therapy with bevacizumab, oxaliplatin, and a fluoropyrimidine (RAISE): a randomised, double-blind, multicentre, phase 3 study. Lancet Oncol. 2015;16(5):499-508.
Ottaiano A, Capozzi M, Tafuto S, et al. Folfiri-aflibercept vs. folfiri-bevacizumab as second line treatment of RAS mutated metastatic colorectal cancer in real practice. Front Oncol. 2019;9:766.
Schwartz LH, Litière S, de Vries E, et al. RECIST 1.1-update and clarification: from the RECIST committee. Eur J Cancer. 2016;62:132-137.
Tournigand C, Cervantes A, Figer A, et al. OPTIMOX1: a randomized study of FOLFOX4 or FOLFOX7 with oxaliplatin in a stop-and-go fashion in advanced colorectal cancer: a GERCOR study. J Clin Oncol. 2006;24(3):394-400.
Chung C, Pherwani N. Ziv-aflibercept: a novel angiogenesis inhibitor for the treatment of metastatic colorectal cancer. Am J Health Syst Pharm. 2013;70(21):1887-1896.
Ciombor KK, Berlin J, Chan E. Aflibercept. Clin Cancer Res. 2013;19(8):1920-1925.
Van Cutsem E, Paccard C, Chiron M, Tabernero J. Impact of prior bevacizumab treatment on VEGF-A and PlGF levels and outcome following second-line aflibercept treatment: biomarker post hoc analysis of the VELOUR trial. Clin Cancer Res. 2020;26(3):717-725.
Huang L, Hu C, Di Benedetto M, et al. Induction of multiple drug resistance in HMEC-1 endothelial cells after long-term exposure to sunitinib. Onco Targets Ther. 2014;7:2249-2255.
Gu Y, Lu H, Boisson-Vidal C, et al. La résistance aux traitements antiangiogéniques - Une actualité clinique et scientifique. Med Sci (Paris). 2016;32(4):370-377.
Emmink BL, Van Houdt WJ, Vries RG, et al. Differentiated human colorectal cancer cells protect tumor-initiating cells from irinotecan. Gastroenterology. 2011;141(1):269-278.
Tandia M, Alili J, Noel-Hudson M, et al. Optimisation thérapeutique par blocage de l'angiogenèse associé à d'autres médicaments anticancéreux (Doxorubucine, Irinotécan, Sorafénib). Pharm Hosp Clin. 2019;54(1):81.
INCa. Le prix des médicaments anticancéreux - Ref: Etatprixmedantik17; 2017. https://www.e-cancer.fr/Expertises-et-publications/Catalogue-des-publications/Le-prix-des-medicaments-anticancereux. Accessed June 28 2022.
Knight B, Rassam D, Liao S, Ewesuedo R. A phase I pharmacokinetics study comparing PF-06439535 (a potential biosimilar) with bevacizumab in healthy male volunteers. Cancer Chemother Pharmacol. 2016;77(4):839-846.
Francisco EM. Onbevzi: Pending EC decision. European Medicines Agency; 2020. https://www.ema.europa.eu/en/medicines/human/summaries-opinion/onbevzi
Kopetz S, Grothey A, Yaeger R, et al. Encorafenib, binimetinib, and cetuximab in BRAF V600E-mutated colorectal cancer. N Engl J Med. 2019;381(17):1632-1643.
Dolatkhah R, Dastgiri S, Eftekhar Sadat AT, Farassati F, Nezamdoust M, Somi MH. Impact of RAS/RAF mutations on clinical and prognostic outcomes in metastatic colorectal cancer. Bioimpacts. 2021;11(1):5-14.
Sinicrope FA, Mahoney MR, Smyrk TC, et al. Prognostic impact of deficient DNA mismatch repair in patients with stage III colon cancer from a randomized trial of FOLFOX-based adjuvant chemotherapy. J Clin Oncol. 2013;31(29):3664-3672.
Rui Y, Wang C, Zhou Z, Zhong X, Yu Y. K-Ras mutation and prognosis of colorectal cancer: a meta-analysis. Hepatogastroenterology. 2015;62(137):19-24.
Pikoulis E, Papaconstantinou D, Pikouli A, Wang J, Theodoridis C, Margonis GA. Reevaluating the prognostic value of RAS mutation status in patients with resected liver metastases from colorectal cancer: a systematic review and meta-analysis. J Hepatobiliary Pancreat Sci. 2021;28(8):637-647.